Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 8/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111265 | 0.86 | REN (0.52) | JAK2JAK1RENCYP3A4KCNH2 | |
| SCHEMBL3103641 | 0.77 | REN (0.41) | JAK2JAK1RENUSP30GPR119 | |
| SCHEMBL1229339 | 0.77 | REN (0.46) | RENCYP3A4KCNH2 | |
| SCHEMBL10183402 | 0.77 | TACR1 (0.44) | JAK2JAK1RENUSP30HSD11B1 | |
| SCHEMBL10183689 | 0.76 | TACR1 (0.43) | JAK2JAK1RENUSP30HSD11B1 | |
| SCHEMBL14026912 | 0.76 | USP30 (0.42) | JAK2JAK1RENUSP30GPR119 | |
| SCHEMBL3108333 | 0.76 | REN (0.48) | RENCYP3A4KCNH2 | |
| SCHEMBL3105266 | 0.76 | REN (0.54) | REN | |
| SCHEMBL5313422 | 0.76 | REN (0.48) | JAK2JAK1RENGPR119CYP3A4 | |
| SCHEMBL8264309 | 0.76 | TACR1 (0.45) | JAK2JAK1RENUSP30HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | JAK2 1993/4885JAK1 1885/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.